GLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents
Open Access
- 23 October 2019
- journal article
- research article
- Published by Wiley in Cardiology Research and Practice
- Vol. 2019, 1-8
Abstract
GLP-1 is a new type of antidiabetic agent that possesses many beneficial effects. Although its cardiovascular actions have been widely examined, little is known about GLP-1’s effects on the rat coronary artery (RCA) or about the mechanisms underpinning these effects. Here, we report that GLP-1 inhibits depolarization- or thromboxane receptor agonist (U46619)-induced RCA contraction in a dosage-dependent manner. Vasorelaxation was attenuated by denuding the endothelium, L-NAME (nitric oxide synthase inhibitor), and glyburide (KATP channel blocker) but was not affected by indomethacin (cyclooxygenase inhibitor), iberiotoxin [Ca2+-activated K+ channel (KCa) blocker], or 4-aminopyridine (KV channel blocker). Furthermore, GLP-1 increased outward K+ currents by enhancing the KATP channel in rat coronary arterial smooth muscle cells (RCASMCs). These results show that GLP-1 is an endothelial-dependent vasospasmolytic agent in the RCA and imply that the relaxant effect is regulated by enhancing KATP rather than KV or KCa currents in RCASMCs.Keywords
Funding Information
- Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province (2015-287, 2017-1389, 2015-110, 201201041, 201801D121202)
- Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province (2015-287, 2017-1389, 2015-110, 201201041, 201801D121202)
- Shanxi Scholarship Council of China (2015-287, 2017-1389, 2015-110, 201201041, 201801D121202)
- Shaanxi Health and Family Planning Commission (2015-287, 2017-1389, 2015-110, 201201041, 201801D121202)
- Applied Basic Research Program in Shanxi Province (2015-287, 2017-1389, 2015-110, 201201041, 201801D121202)
This publication has 33 references indexed in Scilit:
- A Pilot Study to Assess Whether Glucagon-Like Peptide-1 Protects the Heart From Ischemic Dysfunction and Attenuates Stunning After Coronary Balloon Occlusion in HumansCirculation: Cardiovascular Interventions, 2011
- Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion InjuryJACC, 2009
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent PathwaysCirculation, 2008
- The dietary flavonoid quercetin activates BKCa currents in coronary arteries via production of H2O2. Role in vasodilatationCardiovascular Research, 2007
- Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat HeartsThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Effect of Glucagon-Like Peptide-1(7–36) and Exendin-4 on the Vascular Reactivity in Streptozotocin/Nicotinamide-Induced Diabetic RatsPharmacology, 2005
- Thromboxane A 2 -Induced Inhibition of Voltage-Gated K + Channels and Pulmonary VasoconstrictionCirculation Research, 2003
- Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive ratsJournal Of Hypertension, 2003
- Reversal of glibenclamide-induced coronary vasoconstriction by enhanced perfusion pulsatility: possible role for nitric oxideCardiovascular Research, 2000
- Effects of Potassium Channel Blockers on Resting Tone in Isolated Coronary ArteriesJournal of Cardiovascular Pharmacology, 1996